MO8833A_supplementary_materials_v2_tables.pdf (239.75 kB)
Download file

Supplementary Tables – Indirect comparison of pembrolizumab monotherapy versus nivolumab+ipilimumab in first-line metastatic lung cancer

Download (239.75 kB)
dataset
posted on 25.01.2022, 09:05 authored by Figshare Future Science GroupFigshare Future Science Group, Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson, Bilal Piperdi

Table S1

Base case scenario of overall survival and progression-free survival in patients with PD-L1 TPS≥1% before matching

Table S2

Landmark analysis of overall survival and progression-free survival for chemotherapy arms from KN024/KN042 and CheckMate 227 Part 1a in patients with PD-L1 TPS≥1% before and after matching

Table S3

Pembrolizumab versus nivolumab+ipilimumab for overall survival and progression-free survival in patients with PD-L1 TPS≥1%, TPS≥50% and TPS 1–49%

Funding

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

History